New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
17:58 EDTCBSTCubist receives FDA approval for MRSA antibiotic Sivextro
The FDA approved Sivextro, a new antibacterial drug, to treat adults with skin infections. Sivextro is approved to treat patients with acute bacterial skin and skin structure infections, or ABSSSI, caused by certain susceptible bacteria, including Staphylococcus aureus, including methicillin-resistant strains, and methicillin-susceptible strains, various Streptococcus species, and Enterococcus faecalis. Sivextro is available for intravenous and oral use. Sivextro is the second new antibacterial drug approved by the FDA in the past month to treat ABSSSI. Sivextro is marketed by Cubist Pharmaceuticals. Reference Link
News For CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
05:33 EDTCBSTCubist opens international headquarters in Zurich, will invest $400M in R&D
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use